Cloverleaf Bio
cloverleafbio.com
Actively hiring
Drug Discovery
Oncology Therapeutics
Prescription Drugs
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$33M
1 round on record
Latest round
$33M
Seed · Sep 2026 · this month
Team
51-200
employees, estimated range
Hiring now
3
+3 posted in 30 days
Backers
1
Draper Associates
The money's age
Fresh money
0 months since the last round · and hiring
Momentum
75/100
hiring for its size, in the news, fresh money
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Sep 2026 | $33M | — | globenewswire |
Backed byfrom the funds' portfolios and accelerator catalogs
Draper Associates Similar startupsby what they do, their industry and backers
Our team has extensive expertise in kidney disease, targeted delivery of RNA therapeutics, translational systems biology and data sciences…
Learn about how ARTBIO is redefining cancer care through a new class of alpha radioligand therapies and building an ecosystem to maximize…
Mapping Biology to Precise Medicines The best therapeutics are built around the best targets. By analyzing massive datasets from individual…
CyberSwarm is an AI-enabling neuromorphic engineering company that harnesses nature’s intelligence to revolutionize AI.
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…
Visualize live cell function at scale with Pixel™: power cell biology discovery with insights on viability, morphology, ephys, & more.
News
Cloverleaf Bio获种子轮投资_腾讯新闻
2026年9月9日美国tRNA癌症治疗药物研发商Cloverleaf Bio宣布完成种子轮融资本轮融资由4BIO Capital、AbbVie和BIVF联合投资具体融资金额未披露Cloverleaf Bio是一家专注于基于工程化转运RNAtRNA的新型癌症治疗药物研发的公司公司构建了工程化转运RNA药物平台旨在靶向肿瘤依赖的RNA修饰酶开发差异化癌症治...
Read more
Report
Cloverleaf Bio获得3300万美元种子轮融资_腾讯新闻
Cloverleaf Bio是一家tRNA癌症治疗药物研发服务商公司搭建工程化转运 RNA 药物平台靶向肿瘤依赖的 RNA 修饰酶核心管线 CLB-001 针对肝细胞癌在耐药实体瘤模型展现差异化活性同步布局抗体-tRNA 偶联物用于结直肠癌近日Cloverleaf Bio获得3300万美元种子轮融资4BIO Capital领投Boehringer Ingelheim Ven...
Read more
Report
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer TherapeuticsOversubscribed round led by 4BIO Capital includes s...
Read more
Report
Cloverleaf Bio announced that it has received $33 million in funding from a group of investors
Read more
Report
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics Oversubscribed round led by 4BIO Capital includes...
Read more
Report
Tech stack
Technologies named in job postings at Cloverleaf Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
26/100AI adopter
AI & ML
CLIP
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
53/100
Stable
Open positions
3
3 opened / 0 closed in 30 days
ATS activity
Every ~4 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Actively hiring for Science & Research (+3 in 30 days)
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Boston
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
New Haven
United States
HQ
Boston
United States
Engineering / R&D
3 open roles 3 posted in 90 days 100% engineering 50-200 est. staff
hires for Science & Research
Financials
Total raised
$33M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2026 | $33M | Details |